Acute Myelomonocytic Leukemia

Search Trials
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Status:
Active, not recruiting
Last Changed:
Sep 16, 2021
First Changed:
Dec 3, 2010
Disease(s):
Acute Myeloid Leukemia With FLT3/ITD Mutation
Intervention(s):
BiopsyBone Marrow AspirationCytarabineDaunorubicin HydrochlorideLaboratory Biomarker AnalysisQuality-of-Life AssessmentQuestionnaire AdministrationSorafenib Tosylate
Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Status:
Not yet recruiting
Last Changed:
Aug 16, 2021
First Changed:
Aug 6, 2021
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
ClofarabineFludarabineHematopoietic Cell TransplantationTotal-Body IrradiationTreosulfan
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
Status:
Recruiting
Last Changed:
Jan 22, 2021
First Changed:
Dec 16, 2020
Disease(s):
Refractory Acute Myeloid Leukemia
Intervention(s):
CPX-351
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status:
Recruiting
Last Changed:
Oct 28, 2021
First Changed:
Dec 3, 2008
Disease(s):
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Intervention(s):
CytarabineDecitabineFilgrastim-sndzFludarabine PhosphateGemtuzumab OzogamicinIdarubicinLaboratory Biomarker Analysis
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Status:
Completed
Last Changed:
Sep 25, 2017
First Changed:
Dec 6, 2010
Disease(s):
Adult Acute Myeloid Leukemia in Remission
Intervention(s):
Laboratory Biomarker AnalysisLenalidomidePharmacological Study

Connect. Empower. Inspire.